← Back to Clinical Trials
Recruiting NCT07546864

NCT07546864 Comparative Effects of Mirror Therapy and Cognitive Orientation to Daily Occupational Performance in Stroke: A Randomized Controlled Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07546864
Status Recruiting
Phase
Sponsor Hacettepe University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2026-02-15
Primary Completion 2026-05-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mirror TherapyCognitive Orientation to Daily Occupational Performance (CO-OP)Conventional Occupational Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2026-02-15 with a primary completion date of 2026-05-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the effectiveness of three rehabilitation approaches in individuals with stroke: mirror therapy (MT), cognitive orientation to daily occupational performance (CO-OP), and conventional occupational therapy (COT), all combined with robotic balance training. A total of 45 individuals with subacute and chronic stroke will be randomly assigned to one of three groups. Each group will receive 4 weeks of intervention (5 sessions per week), followed by a 3-month follow-up period. Outcomes related to motor function, somatosensory function, activities of daily living, participation, and quality of life will be assessed at baseline, after intervention, and at follow-up. The study aims to determine which intervention approach is more effective in improving functional outcomes in individuals with stroke.

Eligibility Criteria

Inclusion Criteria: * \- Individuals diagnosed with ischemic or hemorrhagic stroke * Age 18 years and older * Subacute (3-6 months post-stroke) or chronic stage (6-12 months post-stroke) * Brunnstrom Motor Recovery Stage ≥3 for upper extremity, ≥4 for hand, and ≥4 for lower extremity * Mini-Mental State Examination (MMSE) score ≥24 * No severe visual, orthopedic, or additional neurological impairments * Not participating in another study during the research period * Voluntary consent to participate in the study Exclusion Criteria: * \- Poor motor coordination or major medical problems that would prevent participation * Presence of Wernicke's aphasia * Botulinum toxin injection within the last 3 months * Psychiatric conditions that may interfere with participation (e.g., depression, ongoing psychiatric treatment, low motivation)

Contact & Investigator

Central Contact

NURTEN BİLGİN, PhD Student

✉ nurtenncek@gmail.com

📞 +905546366542

Principal Investigator

Gokcen Akyurek, Associate Professor

PRINCIPAL INVESTIGATOR

Hacettepe University

Frequently Asked Questions

Who can join the NCT07546864 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07546864 currently recruiting?

Yes, NCT07546864 is actively recruiting participants. Contact the research team at nurtenncek@gmail.com for enrollment information.

Where is the NCT07546864 trial being conducted?

This trial is being conducted at Bayburt, Turkey (Türkiye).

Who is sponsoring the NCT07546864 clinical trial?

NCT07546864 is sponsored by Hacettepe University. The principal investigator is Gokcen Akyurek, Associate Professor at Hacettepe University. The trial plans to enroll 45 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology